Increasing knowledge of cancer genomes has triggered the development of specific targeted inhibitors, thus providing a valuable therapeutic pool. METHODS: In this report, the authors analyze the presence of targetable alterations in 136 tumor samples from 92 patients with melanoma using a comprehensive approach based on targeted DNA sequencing and supported by RNA and protein analysis. Three topics of high clinical relevance are addressed: the identification of rare, activating alterations; the detection of patient-specific, co-occurring single nucleotide variants (SNVs) and copy number variations (CNVs) in parallel pathways; and the presence of cancer-relevant germline mutations. RESULTS: The analysis of patient-matched blood and tumor samples was done with a custom-designed gene panel that was enriched for genes from clinically targetable pathways. To detect alterations with high therapeutic relevance for patients with unknown driver mutations, genes that are untypical for melanoma also were included. Among all patients, CNVs were identified in one-third of samples and contained amplifications of druggable kinases, such as CDK4, ERBB2, and KIT. Considering SNVs and CNVs, 60% of patients with metastases exhibited co-occurring activations of at least 2 pathways, thus providing a rationale for individualized combination therapies. Unexpectedly, 9% of patients carry potentially protumorigenic germline mutations frequently affecting receptor tyrosine kinases. Remarkably two-thirds of BRAF/NRAS wild-type melanomas harbor activating mutations or CNVs in receptor tyrosine kinases. CONCLUSIONS: The results indicate that the integrated analysis of SNVs, CNVs, and germline mutations reveals new druggable targets for combination tumor therapy.
INTRODUCTION
Until recently, only a few therapeutic options with limited efficacy were available for patients with advanced melanoma. Today, B-Raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibitors (targeted therapy) as well as antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) (immunotherapy) are used routinely in the clinic, with patient response rates from 20% to 70% in metastatic melanoma. 1, 2 The decision whether a melanoma patient will receive targeted therapy or immunotherapy depends on several factors. The presence of activating BRAF mutations at position 600 is imperative for the efficacy of the BRAF/MEKinhibitor combination. For patients who have melanomas with other oncogenic genetic aberrations, effective signaling
Cancer February 15, 2019 pathway inhibitors have not yet been approved. Immune therapy is effective in 35% to 60% of patients with melanoma, irrespective of the driver mutation. 3, 4 However, both strategies have their drawbacks. For patients with opposing comorbidities or high tumor load and rapid progress, immunotherapy may not be suitable. Also, considerable percentages of patients suffer from intolerable adverse effects during immunotherapy, forcing them to quit therapy and alter the treatment strategy. 5 Patients who receive BRAF/MEK inhibitors usually develop resistance within 9 to 12 months, despite a good initial tumor response. 2 Therefore, it may be beneficial for patients with melanoma who depend on targeted therapy to identify additional, potentially actionable genomic alterations, allowing the individualization of inhibitor combinations as treatment. Because the melanoma genome is among the tumor genomes with the largest number of accumulated mutations, whole-exome analysis of patient melanomas generates an overwhelming amount of data and is inexpedient for clinical use. However, the exomes and genomes of several hundred previously analyzed melanomas have revealed information about the most frequently mutated genes and potentially relevant melanoma oncogenes and tumor suppressors. 6, 7 These data sources allow the design of a reasonable panel of selected genes, which 1) are relevant for melanoma biology and 2) belong to pathways that can be addressed by pharmaceutical inhibitors that are already approved or under investigation in clinical trials.
For lung cancer, in which the genomic mutation load is almost as high as that in melanomas, panel sequencing has proven to be highly valuable for individualized therapy decisions. 8 Several groups also have analyzed melanomas using panel sequencing with self-designed melanoma panels 9, 10 or commercial cancer hotspot panels. 11, 12 Potentially actionable mutations were identified in all studies. However, the use of cancer hotspot panels limits the detection of genomic alterations to known hotspots, thus leading to an underestimation of tumor-relevant mutations in tumor-suppressor genes. Furthermore, copy number variations (CNVs) frequently go undetected, because most analyses are done on formalin-fixed, paraffin-embedded (FFPE) tissues and without matched normal control DNA samples, rendering the reliable detection of such structural variants very difficult.
Still, examples from other cancer entities demonstrate that the detection of CNVs has high diagnostic relevance and is valuable for therapeutic decisions. 13, 14 Here, we present the analysis of genomic alterations in 45 primary melanomas and 91 metastatic melanomas from 92 patients using a self-designed melanoma panel, which included the protein-coding exons of more than 50 melanoma-relevant and therapy-relevant genes. The comparison with patient-matched blood samples allowed us to detect actionable somatic mutations, CNVs, and germline variants. The patient-wise integration of gained data provides valuable rationales for individualized therapy options.
MATERIALS AND METHODS

Patients
This study was performed according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Medical Faculty, University of Würzburg (study reference: 241/2014). Written informed consent was obtained from each patient. Altogether, 92 patients suffering from primary or metastasized melanoma who received treatment at the Department of Dermatology, University Hospital Würzburg, were included in the study. Where indicated, consecutive metastatic melanoma samples or primary as well as metastatic samples were obtained from individual patients. Detailed accompanying methods are provided in the Supporting Information.
RESULTS
Study Design and Mutation Spectrum
The study was conducted to detect potential tumor drivers in melanomas, with special focus on targetable pathway alterations. We designed a customized gene panel, which contained genomic information of more than 50 genes, including genes with high mutation incidence in melanoma (The Cancer Genome Atlas [TCGA] data; National Cancer Institute, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD) as well as genes that frequently are altered in patients with melanoma upon the development of resistance and that encode targetable pathways (eg, mitogen-activated protein kinase kinase 1 and 2 (MAP2K1 and MAP2K2) (Supporting Fig. 1A ). The panel was optimized twice during the course of the analysis, which led to slight changes in the number and identity of analyzed genes (see Supporting Table 1 ). With the exception of telomerase reverse transcriptase (TERT ), in which we included only the proximal promoter, the entire exons of the chosen genes were sequenced. This setup allowed us to detect both CNVs and somatic and germline mutations (hereafter termed single nucleotide variants [SNVs] ) in patients with melanoma. The effects of potentially actionable CNVs on gene expression were addressed by targeted RNA sequencing (RNASeq), real-time polymerase chain reaction (PCR) analysis, and immunohistochemistry (for an overview, see Supporting Fig. 1B) . . For 7 patients, both primary and metastatic melanoma samples were available, and those patients are included only in the section 'metastatic melanoma'. ALM indicates acral lentiginous melanoma; DM, desmoplastic melanoma; LMM, lentigo maligna melanoma, NM, nodular melanoma; SSM, superficial spreading melanoma. (B) The landscape of recurrent somatic single nucleotide variants (SNVs) and copy number variations (CNVs) is illustrated in primary (purple) and metastatic (green) melanoma samples from individual patients. When more than 1 biopsy per patient was analyzed, only the first acquired tumor is shown to avoid overestimation of the frequency of patent-specific mutations. Data from a formalin-fixed, paraffin-embedded sample were not included because of the low tumor load in the biopsy. (C) The landscape of recurrent somatic SNVs and CNVs is illustrated in primary (purple) and metastatic (green) melanoma samples from patients who had 2 or more consecutive samples. Note that the first of the patient-derived tumors is also represented in B. ALPK2 indicates α kinase 2; ARID2, AT-rich interaction domain 2; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK4, cyclin-dependent kinase 4; CDNK2A, cyclin-dependent kinase inhibitor 2A; ERBB3, Erb-b2 receptor tyrosine kinase 3; ERBB4, Erb-b2 receptor tyrosine kinase 4; FGFR3, fibroblast growth factor receptor 3; GRIN2A, glutamate ionotropic receptor N-methyl-D-aspartic acid-type subunit 2A; GRM3, glutamate metabotropic receptor 3; KDR, kinase insert domain receptor; KIAA1804, mitogen-activated protein kinase kinase kinase 21; KIT, mast/stem cell growth factor receptor Kit; MAP3K9, mitogen-activated protein kinase kinase kinase 9; MET, met proto-oncogene, hepatocyte growth factor receptor; NF1, neurofibromin 1; NRAS, neuroblastoma RAS viral oncogene homolog; PDGFRA, plateletderived growth factor receptor α; PDGFRB, platelet-derived growth factor receptor β; PPP6C, protein phosphatase 6 catalytic subunit; PREX2, phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2; PTEN, phosphatase and tensin homolog; PTPRK, protein tyrosine phosphatase, receptor type K; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; STK19, serine/threonine kinase 19; TERT_prom, telomerase reverse transcriptase promoter; TP53, tumor protein 53; WT, wild type.
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Cancer February 15, 2019 To identify potential tumor-driving alterations in patients with melanoma, we collected 45 snap-frozen primary melanomas and 90 melanoma metastases from 91 patients as well as 1 metastatic FFPE sample from a patient whose tumor was excised at an external institution. For some patients, several melanomas were obtained. Patient characteristics are presented in Figure 1A . For 131 of these 136 tissue samples, corresponding blood samples also were obtained. Detailed sequencing statistics for all samples are available in Supporting Table 2 .
SNVs occurred in most of the genes investigated in the panel. In total, 27 genes (including the TERT promotor) were identified as recurrently mutated in at least 5% of patients (Fig. 1B and Supporting Table 3 ). Figure 1B displays SNVs and CNVs for 1 tumor per patient. In patients who had several tumors, only the first acquired tumor is included. The follow-up samples were considered separately and are presented together with the first acquired sample (Fig. 1C) to get an impression of tumor heterogeneity in patients.
The majority of SNVs led to missense mutations with unknown effects on protein function. To identify SNVs with a high probability of protumorigenic function in tumor development or maintenance, we focused on known activating/oncogenic alterations as well as deleterious mutations. The interpretation of the oncogenic and deleterious character of the SNV mutations was based on publicly available databases (eg, OncoKB, 15 ClinVar [National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD]) and on published research results, as detailed in Table 1 . [16] [17] [18] Activating mutations were identified in 14 genes, most of which were oncogenes. Next to BRAF and neuroblastoma RAS viral oncogene homolog (NRAS) mutations, we identified oncogenic mutations in mast/stem cell growth factor receptor Kit (KIT ), MAP2K2 and MAP2K1, cyclin-dependent kinase 4 (CDK4), isocitrate dehydrogenase 1 (IDH1), Erb-b2 receptor tyrosine kinase 4 (ERBB4), Ras-related C3 botulinum toxin substrate 1 (RAC1), and splicing factor 3b subunit 1 (SF3B1), as expected for melanoma, but also in kinase insert domain receptor (KDR), Kirsten rat sarcoma viral proto-oncogene (KRAS), RAF protooncogene serine/threonine-protein kinase (CRAF), and fibroblast growth factor receptor 3 (FGFR3), which either rarely are mutated in melanoma (KDR, KRAS, CRAF) or, to our knowledge, have not been described previously for this tumor entity (FGFR3) ( Table 1 , Activating/ Oncogenic Mutations). In some cases, these mutations occurred at low frequency, suggesting that only a tumor subclone harbored the respective SNV. Furthermore, deleterious mutations in tumor suppressors were detected in 20 genes and most frequently affected cyclin-dependent kinase inhibitor 2A (CDKN2A) (8 patients), AT-rich interaction domain 2 (ARID2) (7 patients), neurofibromin 1 (NF1) (6 patients), and phosphatase and tensin homolog 
Abbreviations: AKT3, AKT serine/threonine kinase 3; ARID2, AT-rich interaction domain 2; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK4, cyclin-dependent kinase 4; CDNK2A, cyclin-dependent kinase inhibitor 2A; CRAF, RAF proto-oncogene serine/threonine-protein kinase; del, deletion; ERBB2, Erb-b2 receptor tyrosine kinase 2; ERBB3, Erb-b2 receptor tyrosine kinase 3; ERBB4, Erb-b2 receptor tyrosine kinase 4; FBXW7, F-box and WD repeat domain containing 7; FGFR2, fibroblast growth factor receptor 2; FGFR3, fibroblast growth factor receptor 3; fs, frameshift; GNAQ, G protein subunit αQ; GRIN2A, glutamate ionotropic receptor N-methyl-D-aspartic acid-type subunit 2A; GRM3, glutamate metabotropic receptor 3; IDH1, isocitrate dehydrogenase 1; ins, insertion; KDR, kinase insert domain receptor; KIT, mast/stem cell growth factor receptor Kit; KMT2A, lysine methyltransferase 2A; KRAS, Kirsten rat sarcoma viral protooncogene; MAP2K1, mitogen-activated protein kinase kinase 1; MAP2K2, mitogen-activated protein kinase kinase 2; MET, met proto-oncogene, hepatocyte growth factor receptor; NF1, neurofibromin 1; NRAS, neuroblastoma RAS viral oncogene homolog; PDGFRA, platelet-derived growth factor receptor α; PPP6C, protein phosphatase 6 catalytic subunit; PTEN, phosphatase and tensin homolog; PTPRK, protein tyrosine phosphatase, receptor type K; RAC1, Ras-related C3 botulinum toxin substrate 1; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; SF3B1, splicing factor 3b subunit 1; TP53, tumor protein 53. a Interpretation of the activating/oncogenic mutations is based on information from OncoKB, ClinVar, or www.cancerhotspots.org (as of 09/18), with the exception of BRAF-K499N, for which this information was derived from Ng et al. 16 All alterations are predicted to be oncogenic or likely oncogenic. b Mutations were considered deleterious because of their annotation in OncoKB or the presence of early stop codons or splice site mutations, with the exception of the CDKN2A glutamic acid to glycine mutation at codon 69 (E69G), for which information about the deleterious nature of the mutation is from McKenzie et al 17 and Kannengiesser et al. 18 The asterisk marks samples, in which the mutations were detected at very low frequency (2-5%), but were considered true due to their hotspot character.
Cancer February 15, 2019 and correlating patient parameters are listed. Only rare variants with a frequency <0.5% in 1000 Genomes were considered germline SNVs. The asterisk marks a patient who developed metastases in addition to the investigated primary melanoma during the course of the disease. In the melanoma samples from each patient, germline variants are accompanied by the indicated oncogenic drivers. Superscript numerals in the column headed "Effect" indicate the following references: 1) Liu et al, 25 2) Kress et al, 26 3) Mantelli et al, 27 4) Ghiorzo et al 28 . For patient MS126, the tumor content in the sequenced tissue was below 5%, but the patient was still included because of the reliable detection of oncogenic drivers (www.cbioportal.org, 09/18). ALM indicates acral lentiginous melanoma; LMM, lentigo maligna melanoma; MEN, multiple endocrine neoplasia; MEN2A, multiple endocrine neoplasia, type 2A; Met, metastasis; MIS, melanoma in situ; MM, malignant melanoma; NM, nodular melanoma; panc., pancreatic; PD, predisposition; PM, primary melanoma; SSM, superficial spreading melanoma. (B) This is a 2-dimensional schematic overview of the proteins. SNVs that were identified in the current study are set in boldface. (Table 1 , Deleterious Mutations). The number of NF1 mutations in our cohort appeared to be rather low. However, when we only compared the cutaneous melanomas from our data set with the Skin Cutaneous Melanoma TCGA cohort (PanCancer Atlas dataset), the frequencies of NF1 mutations did not differ significantly between the data sets (Fisher exact test; P = .07).
Mutations Associated With Pre-Existing or Acquired BRAF/MEK-Inhibitor Resistance
Of the 55 patients with metastatic disease and available fresh-frozen tumor material, 11 individuals suffered from disease progression after combined BRAF/MEK-inhibitor treatment during our study. We analyzed at least 1 tumor per patient after progression and focused on somatic alterations, which occurred in addition to the BRAF valine-to-glutamic acid mutation at codon 600 (V600E) (Supporting Table 4 ). In 6 patients, we identified activating mutations in MAP2K1 (MEK1), MAP2K2 (MEK2), and NRAS as well as a BRAF amplification, all of which were associated previously with acquired resistance. [19] [20] [21] [22] [23] One patient harbored the activating KRAS alanineto-valine mutation at codon 146 (A146V). Two patients harbored mutations in MAP2K1 that already coexisted with the BRAF-V600E mutation before the initiation of BRAF-inhibitor therapy. The MAP2K1 alterations proline-to-leucine at codon 124 (P124L) and glycine-toserine at codon 176 (G176S) were identified previously in pretreatment melanoma biopsies and likely are associated with a reduced response to targeted therapy. 22, 24 The CRAF (also RAF1) glycine-to-aspartic acid mutation at codon 535 (G535D); the NF1 leucine-to-phenylalanine mutation at codon 1569 (L1569F); and the KIAA1804 (also MLK4) lysine-to-glutamic acid mutation at codon 283 (K283E) have not previously been described. Because the observed RAF1-G535D mutation affects the kinase domain, we tested its effect on BRAF-inhibitor and MEK-inhibitor resistance. The MEK2 cysteine-to-serine mutation at codon 125 (C125S) served as positive control. Doxycycline-inducible MEK2-C125S, RAF1, and RAF1-G535D were transferred into the melanoma cell line M14, and pathway activation was monitored by Western blot analysis. Although MEK2-C125S activated downstream extracellular signal-regulated kinase 1 (ERK1)/ERK2 and reduced sensitivity to a BRAF/MEK-inhibitor combination (Supporting Fig. 2A,B) , neither RAF1 nor RAF1-G535D had an impact on ERK1/ERK2 activation or sensitivity (Supporting Fig. 2C-F) . Hence, RAF1-G535D is likely a bystander mutation. However, our gene panel enabled the detection of the majority of genetic resistance mechanisms.
Germline Mutations
The availability of blood samples allowed us to detect rare protein-altering germline variants. Surprisingly, 8 of 92 patients with melanoma (9%) harboured germline SNVs, which resulted in amino-acid modifications that previously were associated with cancer predisposition phenotypes or growth abnormalities ( Fig. 2A,B) . [25] [26] [27] [28] [29] [30] [31] [32] According to data from the "1000 Genomes" project, all variants occur at a frequency of less than 5 per 1000 in the general population. Two patients carried the CDKN2A glycine-to-tryptophan mutation at codon 101 (G101W) variant, which is considered oncogenic because of an impaired interaction with CDK4/CDK6. 33 This variant predisposes its carriers to familial melanoma and pancreatic cancer. 27 There were no records of pancreatic cancer for the 2 patients who carried this variant, but both had more than 1 primary melanoma.
All other germline variants affected different receptor tyrosine kinases (RTKs). The observed MET variant with a threonine-to-isoleucine mutation at codon 1010 (T1010I) and Ret proto-oncogene (RET) variant with a tyrosine-to-phenylalanine mutation at codon 791 (Y791F) are likely connected to cancer predisposition; in addition, it has been demonstrated in functional in vitro studies that they convey protumorigenic features, such as transformation and enhanced migration. 24, 31 The ERBB2 isoleucine-to-valine mutation at codon 654 (I654V) and the FGFR1 isoleucine-to-threonine mutation at codon 300 (I300T) have not been functionally tested, but ERBB2-I654V is significantly associated with an increased risk of familial breast cancer. 32 FGFR-I300T was previously observed in a patient with craniofaciosynostosis, which is a skeletal abnormality that occurs during development because of the altered activity of mutant FGFR1, FGFR2, or FGFR3. 26 The sole presence of the germline variants presumably is not sufficient to explain melanoma development. However, we also detected acquired oncogenic mutations in the corresponding tumors from all 8 patients, affecting G-protein subunit α11 (GNA11), BRAF, NRAS, KIT, and NF1, respectively ( Fig. 2A) .
CVNs and Corresponding Gene Expression
Our strategy of including patient-matched blood samples in the analyses allowed us to detect somatic CNVs (Fig. 1B,C and Supporting Table 5 ). Deletions were identified most frequently in the tumor suppressors CDKN2A, protein phosphatase 6 catalytic subunit (PPP6C), and PTEN. Amplifications occurred repeatedly in CDK4, KIT, and KDR. Because one objective of the current study was to identify targetable alterations, we focused on tumor samples from patients who had metastases. Combining SNV and CNV data, we compiled a pathway matrix with potentially targetable alterations in the most melanoma-relevant pathways for each patient. Genes that we considered for each pathway were BRAF, MAP2K1, and MAP2K2 (pathway: BRAF/MEK); NRAS, NF1, and KRAS (pathway: RAS); PTEN, phosphatidylinositol 3-kinase, catalytic α polypeptide (PIK3CA), and AKT serine/threonine kinase 3 (AKT3) (pathway: PI3K); CDKN2A and CDK4 (pathway: CDK4); and KIT (pathway: KIT) (Fig. 3A) . Only such alterations that have been associated with activation of the respective attributed pathway were included (e.g., deleterious CDKN2A mutations, CDKN2A deletion, or CDK4 amplification would all result in CDK4 pathway activation 34 ). Although most pathway activations were predicted based on SNVs in the RAF/MEK and RAS pathways, CNV-dependent alterations strongly contributed to the pathway matrix, particularly in the CDK4 pathway in Figure 3A . When we considered the entire population of patients with metastatic melanoma, it became clear that most of the driver events co-occurred with at least 1 more oncogenic mutation of the selected pathway genes (27 of 48 patients; 56%) (Fig. 3A,B) . This trend was detectable for all melanomas with well known driver mutations, such as mutated BRAF-V600, mutated NRAS-Q61, and NF1 or KIT as drivers, although the latter 2 groups were rare in our cohort. By using the same strategy of selecting oncogenic alterations in our set of genes, we confirmed our data using the TCGA Pan-Cancer Atlas data set, in which 65% of melanomas that had BRAF, NRAS, NF1, and KIT as drivers co-occurred with mutations in at least 1 other pathway, most frequently affecting PTEN or CDKN2A (see the TCGA Pan-Cancer Atlas data set [available at: https://cancergenome.nih. gov] and the cBioPortal for Cancer Genomics 35, 36 [available at: www.cbioportal.org]) (09/18).
To verify the impact of CNVs on gene expression, we isolated RNA from all melanoma metastases for which sufficient material was available (40 samples) and investigated the RNA expression levels of therapy-relevant genes by using targeted RNA sequencing or real-time PCR. The 2 samples that had PTEN deletions displayed very low levels of RNA expression (Supporting Fig. 3 ). In 10 of 11 samples in which a CDKN2A deletion was detected, CDKN2A expression virtually was lost ( Supporting Fig. 4A) . Furthermore, the melanoma sample with CDK4 amplification exhibited the highest level CDK4 expression (Supporting Fig. 4B) . We also performed immunohistochemistry staining of cyclin D1, the regulatory subunit of CDK4, as a marker for CDK4 abundance, because nuclear cyclin D1 is required for CDK4 activity. 34 In line with our observations, deletion of CDKN2A or amplification of CDK4 was identified in 3 of 4 melanomas with the highest cyclin D1 expression (Supporting Fig. 4C ). However, we also observed high cyclin D1 expression in a melanoma sample without genomic alterations of CDKN2A or CDK4 (MS114) (Supporting Fig. 4C ), indicating that other factors, such as CDKN2A promoter methylation or the upregulation of cell cycle-promoting transcription factors, also might contribute to cyclin D1 expression in melanoma. 37, 38 TERT expression was only connected to amplification, but it was independent of promoter mutations, as detected by RNASeq and real-time PCR (Supporting Fig. 5A,B) . Because TERT amplification was detected in all 3 samples from patient MS204, who had established BRAF/MEK-inhibitor resistance, we tested whether TERT contributes to drug resistance. We chose the melanoma cell line UACC-62, which expresses no detectable endogenous TERT (Supporting Fig. 5C ), and transfected this cell line with a doxycycline-inducible TERT plasmid (Supporting Fig. 5D ). TERT induction was not associated with a change in susceptibility toward BRAF or MEK inhibition (Supporting Fig. 5E ), suggesting that it provides no advantage in the development of therapy resistance.
Apart from these repeatedly occurring alterations, we focused on rarely observed, targetable CNVs, such as KIT and ERBB2 amplifications, which were detected in individual patients. Amplification of KIT was associated with high RNA and protein expression levels in a patient with an unknown primary melanoma (MS170_1) (Fig. 4A,C) . We also could detect high levels of KIT expression in a sample with an activating KIT leucine-to-proline mutation at codon 576 (L576P), which was derived from a mucosal melanoma (MS175_1) (Fig. 4C) . The ERBB2 amplification occurred in a metastatic melanoma, which was the only desmoplastic melanoma sample in the cohort (MS106_1). Remarkably, ERBB2 expression was either absent or barely above the detection limit in all other samples, with the exception of MS106, in which ERBB2 expression was massively induced, as confirmed by both RNASeq and immunohistochemistry (Fig. 4B,C) .
Cancer February 15, 2019 Figure 4 . Charts illustrate the correlation of copy number variations (CNVs) and gene expression in receptor tyrosine kinases (A) Real-time polymerase chain reaction analysis of KIT is illustrated for the indicated melanoma samples. Each analysis was performed in duplicate, and β-actin served as the reference. The data were normalized to the median delta cycle threshold (Δ-cT) value of all samples. (B) ERBB2 expression was measured by targeted RNA sequencing for the melanoma samples indicated. Read counts were normalized according to the following procedure: In each melanoma sample, read counts of the target gene were divided by the total number of reads per sample. This value was then multiplied by the number of total reads of the sample with the lowest total read count (amp indicates a sample with CNV amplification), as detected by panel sequencing. (C) Photomicrographs depict immunohistochemistry of KIT and ERBB2 in melanoma samples from the indicated samples (amp indicates a sample with CNV amplification). KIT staining was performed using a peroxidase-coupled detection system, and positive cells are stained in red. ERBB2-positive cells were detected using the Roche Ultra View a 3,3′-diaminobenzidine detection kit (Roche Diagnostics GmbH, Mannheim, Germany) and are stained in brown. ERBB2 does not have a ligand-binding domain and needs a dimerization partner to be able to respond to exogenous growth factors. The analysis of patient melanoma samples, including MS106_1, revealed strong expression of epidermal growth factor receptor (EGFR), a potential binding partner of ERBB2 (Fig. 5A) . We used the melanoma cell line A375 as a reference for EGFR expression, because we previously demonstrated functional EGFR signaling in this cell line. 39 EGFR was detected in all tested melanoma samples, but there was a trend toward higher expression levels in the samples without BRAF-V600E/K mutations (Fig. 5A) .
To test whether aberrant ERBB2 expression enhances tumorigenic features in nontransformed melanocytic cells and thus acts as tumor driver, we engineered nontransformed murine melanocytes, which expressed exogenous EGFR, 40 with doxycycline-inducible ERBB2 (Fig. 5B) . The induction of ERBB2 increased proliferation, as determined by 1-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, even in the absence of epidermal growth factor (EGF) (Fig. 5C ). Western blot analysis revealed that ERBB2 has a strong effect on the PI3K/AKT pathway, because basal phosphorylated AKT (P-AKT) levels were elevated in ERBB2-expressing cells, and EGF-induced P-AKT was elevated and maintained for an extended time compared with control cells (Fig. 5D ). P-ERK1/ERK2 signaling was increased only slightly, and only in the presence of EGF. Furthermore, migration capacity was strongly increased in the presence of EGF (Fig. 5E ). These data suggest that ERBB2 can serve as a tumor-promoter driver in patients who have melanoma with high ERBB2 expression.
The subgroup of patients with no hotspot mutations in NRAS and BRAF is less understood and has the highest clinical need. Twelve of the patients with metastatic melanoma in our cohort belong to this group. Considering activating somatic and germline mutations as well as CNVs, 8 of 12 patients had activating alterations of RTKs (Fig. 5F,G) . In addition, we analyzed our whole patient cohort (including those with primary and metastatic melanomas) as well as the TCGA melanoma cohort (available at: https://cancergenome.nih.gov and www.cbioportal.org) with respect to somatic activating alterations in all RTK genes from our panel (EGFR, ERBB2, ERBB3, ERBB4, MET, IGF1R, KIT, KDR, FGFR1, FGFR2, FGFR3, RET, PDGFRA, PDGFRB, and ROS1). The activating nature of the mutations was based on information from cBioPortal and OncoKB. Tumors that carried wild-type BRAF and NRAS (including a few tumors with nonhotspot mutations in both genes) were enriched significantly for activating RTK alterations (Fisher exact test; P = .0005 for our entire patient cohort; P = .003 for all cutaneous melanomas from our cohort; and P = .0001 for the TCGA data set). Because specific inhibitors are available or in clinical studies for all affected RTKs, we strongly support routinely conducted genomic analyses of RTKs for this patient subgroup.
Altogether, our study has revealed actionable alterations in a large fraction of patients from all melanoma subgroups. Considering only those therapy options that either have been approved or are available for melanoma patients through clinical studies, our combined analysis of SNVs and CNVs has revealed rational targeted therapy options for 24 of 56 patients with metastatic melanoma (Supporting Table 6 ).
In the future, more therapy options will become available, thus providing a strong rationale for performing deep-sequencing analyses of therapy-adapted gene targets. We were able to establish that the joint detection of SNVs, CNVs, and germline variants constitutes a valuable and reliable source for future therapy decisions.
Conclusion
In this report, we describe the development and validation of a targeted sequencing panel focused on the most relevant genetic alterations in melanoma and on genes that affect signaling pathways and thus can be targeted by pharmacologic inhibitors. The combination of CNVs with activating or deleterious mutations enabled us to create a pathway matrix, which illustrates the predicted activated signaling pathways for each patient. Importantly, the majority of our patients harbored genomic changes, which led to at least 2 pathway alterations. We propose that a targeted, deep-sequencing approach with careful consideration of oncogenic and deleterious SNVs and CNVs will help to identify patients who might benefit from a combination of BRAF/MEK inhibitors with an individually determined "inhibitor X" from the very beginning of their treatment. The CDK4 pathway in particular was altered in greater than 40% of patients who had metastases, including the majority of those with NRAS-mutant tumors. Next to this expected pathway and other frequently altered pathways, as described previously, 12, [41] [42] [43] [44] we also observed surprisingly high expression levels of the RTKs ERBB2 and KIT in individual patients. Although ERBB2 expression is uncommon in melanomas (www.proteinatlas.org), 45 it appears that high expression levels are caused by amplifications of the genomic locus. In breast and stomach cancers, high ERBB2 levels are associated with rapid tumor growth and metastatic spread and provide the rationale for targeting ERBB2 by treatment with trastuzumab and lapatinib. 46, 47 In a preclinical study of wild-type BRAF/ NRAS but ERBB2-positive melanoma cell xenografts, it was demonstrated that ERBB2 dimerized with ERBB3, and tumor growth could be reduced significantly in vivo with the ERBB2-specific antibody pertuzumab. 48 KIT can be targeted by small-molecule inhibitors, such as imatinib, which are approved for the treatment of gastrointestinal sarcomas with mutations in exon 11, encompassing the juxtamembrane region with amino acids 550 through 591. 49 Melanoma patients with mutated KIT also might benefit from imatinib, but this was not confirmed for patients with amplified KIT. 50 However, that study only encompassed 11 patients, and imatinib was received as monotherapy. In our study, the patient who had KIT-amplified metastatic melanoma also harbored a deleterious CDKN2A mutation, and a combination of KIT and CDK4/CDK6 inhibitors might improve efficacy. Different dual-therapy regimens have been tested in preclinical mouse models with promising results. It has been demonstrated that the identification of genetic variants (other than BRAF-V600E) was useful for designing second-line combination therapies, which clearly reduced tumor load. [51] [52] [53] [54] In addition to the somatic alterations described above, we observed significant numbers of rare germline variants, which occur at frequencies below 5 per 1000 in the general population. The variants are associated with protumorigenic features and occur in CDKN2A as well as in RTKs like RET, FGFR1, and MET. Among these variants, CDKN2A is the only gene that was previously associated with familial melanoma. 55 Although RET, FGFR1, and MET are not considered melanoma targets, affected patients may benefit from RTK inhibitors. The RET-targeting multikinase inhibitor cabozantinib is clinically approved for the treatment of renal cell carcinoma and medullary thyroid carcinoma. 56, 57 In addition to RET, cabozantinib also inhibits MET and KIT. FGFR1 can be blocked by lenvatinib, an RTK inhibitor that is approved for the treatment of renal cell carcinoma. In the patient who had the deleterious CDKN2A mutation, inhibition of the CDK4/CDK6 pathway (e.g., by palbociclib or ribociclib, which currently are approved or being investigated in clinical trials) would be a rational option. All germline mutations were accompanied by tumor-specific driver mutations. This opens up new avenues for combinatorial treatment of germline and somatic SNVs. Routine testing for germline variants in patients with melanoma may provide additional health benefit by stimulating preventive measures for the patient's family members.
In summary, we propose that comparative, targeted sequencing of melanoma and blood cells provides a valuable means for in-depth analysis of targetable somatic and germline SNVs and CNVs. Our current data suggest that the inclusion of genes like ERBB2, KIT, FGFR3, and RET, which are targets of approved pharmacologic therapies in other cancer types but are considered atypical for cutaneous melanoma, might be relevant in the treatment of individual patients. Particularly in patients who have non-NRAS/ non-BRAF-V600 mutations, activated RTKs are frequently identified. With growing insight into the tolerability of drug combinations tested in clinical cancer trials, safer individual drug combinations likely will be available for patients in the near future.
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